For the quarter ending 2025-09-30, IBO had -$612K decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Loss from operations | - | -15,631 |
| Net (loss) income | -17,105 | - |
| Depreciation and amortization | 288 | 571 |
| Stock based compensation | 1 | 4 |
| Issuance of shares for professional services rendered | 0 | 190 |
| Accrued interest on notes payable | 262 | 531 |
| Change in fair value of note payable, related party | 268 | 12,942 |
| Accounts receivable | 15 | -4 |
| Inventory | -1 | -3 |
| Prepaid expenses and other current assets | 35 | -98 |
| Accounts payable | 22 | -159 |
| Accrued expenses | 69 | 71 |
| Net cash used by operating activities | -613 | -1,376 |
| Payments received on notes receivable | 1 | 1 |
| Net cash provided by investing activities | 1 | 1 |
| Borrowings on note payable, related party | - | 0 |
| Net cash provided by financing activities | - | 0 |
| Net increase (decrease) in cash | -612 | -1,375 |
| Cash and cash equivalents at beginning of period | 1,999 | - |
| Cash and cash equivalents at end of period | 12 | - |
IMPACT BIOMEDICAL INC. (IBO)
IMPACT BIOMEDICAL INC. (IBO)